Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain; and SAGE-689, a novel GABAA receptor positive allosteric modulator that is in preclinical stage to treat acute and chronic CNS disorders. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-299-8380
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$90.27 million
Profitability
Miscellaneous
Employees637
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions
What is SAGE Therapeutics' stock symbol?
SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."
How were SAGE Therapeutics' earnings last quarter?
SAGE Therapeutics Inc (NASDAQ:SAGE) announced its quarterly earnings data on Tuesday, February, 19th. The biopharmaceutical company reported ($3.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($2.89) by $0.49. The biopharmaceutical company earned $0.27 million during the quarter. During the same quarter in the previous year, the firm earned ($1.75) EPS. View SAGE Therapeutics' Earnings History.
When is SAGE Therapeutics' next earnings date?
What price target have analysts set for SAGE?
12 Wall Street analysts have issued 12 month price objectives for SAGE Therapeutics' shares. Their forecasts range from $80.00 to $261.00. On average, they anticipate SAGE Therapeutics' stock price to reach $201.4545 in the next twelve months. This suggests a possible upside of 29.1% from the stock's current price. View Analyst Price Targets for SAGE Therapeutics.
What is the consensus analysts' recommendation for SAGE Therapeutics?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 1 sell rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SAGE Therapeutics.
What are Wall Street analysts saying about SAGE Therapeutics stock?
Here are some recent quotes from research analysts about SAGE Therapeutics stock:
- 1. Canaccord Genuity analysts commented, "We like the setup heading into a catalyst-rich 2H18/2019E We are updating our model after SAGE reported its 1Q18 and provided a corporate update today (5/3). With its first product, brexanolone IV for postpartum depression (PPD), filed with potential commercialization in 1H19, and a robust pipeline of neuro- focused assets led by SAGE-217, our BUY thesis on the stock remains unchanged. In short, we like SAGE’s pipeline that targets several large central nervous system (CNS) indications where the unmet need is high (e.g., major depressive disorder, PPD, Parkinson’s, etc.) and the scarcity value that comes with robust/ripening CNS platforms. With the stock having pulled back ~25% since its 52-week high on 1/31/18, we like the setup heading into a catalyst-rich 2H18/2019E. Our DCF-based price target remains unchanged at $210." (5/3/2018)
- 2. Cowen Inc analysts commented, "We note that neither Mylan nor Biocon would comment on Neulasta’s updated timing. We spoke with a manufacturing consultant who believed that biosimilar Neulasta would not receive an approval until the Form 483 issues were resolved. We expect an update on Mylan’s earnings call on Wednesday, 5/9/18. Biocon Form 483: Biocon announced yesterday (5/1/18) that the FDA issued a Form 483 with 7 observations relating to the company’s Bangalore, India site. As a reminder, MYL has a partnership with Biocon to produce biosimilars Neulasta/Herceptin out of the same facility. The TAD for biosimilar Neulasta is on 6/4/18. Biocon noted that the observations were largely procedural and aimed at continuous improvement. Further, the company indicated that it would respond to the FDA well within" the typical 15 day response period." (5/3/2018)
Has SAGE Therapeutics been receiving favorable news coverage?
Media headlines about SAGE stock have trended somewhat negative on Wednesday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. SAGE Therapeutics earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the immediate future.
Who are some of SAGE Therapeutics' key competitors?
Some companies that are related to SAGE Therapeutics include Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Ionis Pharmaceuticals (IONS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Beigene (BGNE) and Jazz Pharmaceuticals (JAZZ).
What other stocks do shareholders of SAGE Therapeutics own?
Who are SAGE Therapeutics' key executives?
SAGE Therapeutics' management team includes the folowing people:
- Dr. Jeffrey M. Jonas, CEO, Pres & Director (Age 66)
- Ms. Kimi E. Iguchi, CFO & Treasurer (Age 57)
- Ms. Anne Marie Cook, Sr. VP, Gen. Counsel & Sec. (Age 57)
- Dr. Stephen J. Kanes, Chief Medical Officer (Age 54)
- Mr. Michael Cloonan, Chief Bus. Officer (Age 48)
Who are SAGE Therapeutics' major shareholders?
SAGE Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (14.94%), BlackRock Inc. (5.35%), Bank of New York Mellon Corp (3.91%), BB Biotech AG (2.93%), Eagle Asset Management Inc. (1.38%) and American Century Companies Inc. (1.13%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for SAGE Therapeutics.
Which institutional investors are selling SAGE Therapeutics stock?
SAGE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Lord Abbett & CO. LLC, Tekla Capital Management LLC, Eversept Partners LP, Fiera Capital Corp, Mackenzie Financial Corp, Chartwell Investment Partners LLC and Oak Ridge Investments LLC. Company insiders that have sold SAGE Therapeutics company stock in the last year include James M Frates, Kevin P Starr, Kimi Iguchi, Stephen Kanes and Steven M Paul. View Insider Buying and Selling for SAGE Therapeutics.
Which institutional investors are buying SAGE Therapeutics stock?
SAGE stock was acquired by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Norges Bank, BB Biotech AG, Bank of New York Mellon Corp, RTW Investments LP, Perceptive Advisors LLC, Strs Ohio and American Century Companies Inc.. View Insider Buying and Selling for SAGE Therapeutics.
How do I buy shares of SAGE Therapeutics?
Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SAGE Therapeutics' stock price today?
One share of SAGE stock can currently be purchased for approximately $156.10.
How big of a company is SAGE Therapeutics?
SAGE Therapeutics has a market capitalization of $7.35 billion and generates $90.27 million in revenue each year. The biopharmaceutical company earns $-372,880,000.00 in net income (profit) each year or ($8.08) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.
What is SAGE Therapeutics' official website?
How can I contact SAGE Therapeutics?
SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]
MarketBeat Community Rating for SAGE Therapeutics (NASDAQ SAGE)
MarketBeat's community ratings are surveys of what our community members think about SAGE Therapeutics and other stocks. Vote "Outperform" if you believe SAGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
